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1. Introduction 
Nearly 60 years after the first successful organ transplantation in humans, it has been an 
exponential increase in our understanding of the immunological processes involved in 
organ transplantation. This knowledge has resulted in the identification of immunogenic 
drug targets and improvement on the management of patient’s surveillance. The past 5 
decades have also seen an explosive evolution in the fields of molecular biology, chemistry 
and informatics that have enabled increased data throughput, permitting the study of 
complete sets of molecules with increasing speed and accuracy using the omics techniques 
such as, genomics (DNA), transcriptomics (RNA), proteomics (proteins) and metabolomics 
(metabolites) (Bañón-Maneus et al 2007) 
Despite overall improvements in immunosuppression regimens, chronic allograft 
dysfunction (CAD) continues to have a negative impact on graft and patient survival, even 
with the use of appropriate doses of immunosuppressive drugs to prevent acute rejection. 
Successful management requires an early detection along with adequate treatment. 
(Hariharan et al 2000 and Meier-Kriesche et al 2004) 
Available diagnostic methods include clinical presentation, biochemical parameters and 
biopsies. Currently, the only non-invasive biomarkers for follow up the kidney graft are 
serum creatinine, glomerular filtration rate (GFR) and proteinuria but neither is particularly 
sensitive or specific and may not reflect early changes. At present, biopsy allograft is 
regarded as the gold standard for the diagnosis of CAD allowing its early detection; 
however, this is a costly procedure which is associated with clinical complications (Ojo et al 
2000 and Nankivell et al 2003). The patient’s management would be facilitated if there were 
appropriate biomarkers enabling the diagnosis or prognosis of different states throughout 
the post transplant course. At that point the proteomics have emerged as a really useful 
technology for biomarker discovery. 
2. Urine as a source of biomarkers 
The Biomarkers Definitions Working Group, defined Biomarker as a molecule that it is a 
characteristic, objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes or pharmacological responses (Biomarkers Definitions 
Working Group, 2001). The ideal biological sample for detecting biomarkers is the so-called 
“proximal fluid”, the bio fluid in closest contact with the site of disease (Decramer et al 
2008). Then, in the context of kidney transplantation the closest biological sample, besides 
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the biopsy, is the urine which represent a fairly simple, non-invasive and inexpensive 
method for obtaining suitable samples for biomarker analyses, and presents a huge 
advantage as it can be performed regularly and frequently if necessary. 
The human kidney (Fig. 1) is composed of 1 million nephrons, which can be divided in two 
functional parts: the glomerulous, which filters the plasma yielding the “primitive” urine, 
and the renal tubule, which reabsorbs most of the primitive urine. However, more than 99% 
of this primitive urine is reabsorbed. The remainder (the urine) exits the kidney via the 
urethra into the bladder (Fig. 1) (Decramer et al 2008). Therefore urine may contain  
 
 
 
 
Fig. 1. Urinary proteins origin. Human kidney it is constituted by nephrons. The plasma 
filtration occurs into the glomerulus and the reabsorption into the tubule. The urine 
generated exits the kidney via urethra into the bladder. (Adapted Decramer et al 2008) 
(images from www. turbosquid.com and www.ratical.org)  
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information not only from the kidney and the urinary tract but also from more distant 
organs via plasma obtained by glomerular filtration. In healthy individuals, 70% of the 
urinary proteome originates from the kidney and the urinary tract, whereas the remaining 
30% represents proteins filtered by the glomerulus (Thongboonkerd and Malasit 2005). 
For these reasons urine is defined as "fluid biopsy" of the kidney and urogenital tract, and 
many of the changes in kidney and urogenital tract can be detected in the urinary proteome. 
Furthermore, as blood filtering, urine contains protein components that are similar to those 
found in the blood. Thus, pathological changes occurring in other organs can be detected in 
blood plasma and, therefore, can be detected in the urinary proteome. NHGRI (National 
Human Genome Research Institute) has said that the study of proteomics of fluids is one of 
the most promising tools for the development of noninvasive tools for early detection of 
human diseases. Human urine is a fluid that contains immediately accessible useful 
biomarkers, it is easy to obtain, non invasive, could be stored for long time and other 
advantages described into Table 1. But the urine has some disadvantages too.  
 
ADVANTAGES DISADVANTAGES 
- can be obtained in large quantities 
using non-invasive procedures 
- easy assessment of reproducibility or 
improvement in sample preparation 
protocols 
- urinary peptides and lower 
molecular mass proteins are 
generally soluble. (Solubilization of 
these low molecular weight proteins 
and peptides is a process with a 
major influence on the proteomics 
analysis) 
- > 30 KDa compounds can be 
analyzed in a mass spectrometer 
without additional manipulation 
- urinary protein is relatively stable 
probably due to the fact that urine 
“stagnates” for hours in the bladder  
- can be stored for several years at -80 
°C without significant alteration of 
its proteome 
- not only the changes in the kidney 
and genitourinary tract are reflected 
by changes in the urinary proteome 
but also changes at more distant sites 
- it widely varies in protein and peptide 
concentrations mostly because of 
differences in the daily intake of fluid 
- standardization based on creatinine or 
peptides generally present in urine  
- definition of disease-specific biomarkers 
in urine, is complicated by significant 
changes in the proteome during the day 
- changes are likely caused by variations 
in the diet, metabolic or catabolic 
processes, circadian rhythms, and 
exercise as well as circulatory levels of 
various hormones  
Table 1. Advantages and disadvantages of urine as source of biomarkers (Decramer et al 
2008, Fliser et al 2005, Kolch et al 2005,  Omenn et al  2005, Schaub et al 2004, Schiffer et al 
2006, and Theodorescu et al 2006) 
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Clinical proteomics is growing significantly in recent years due to the prospect of 
identifying new targets for treatment and therapeutic intervention and biomarkers for 
diagnosis, prognosis, and therapeutic efficacy using technologies that allow us to compare 
proteomic profiles between different conditions pathophysiology. The measurement of 
protein in the urine has been used for many years for the diagnosis and monitoring of many 
kidney diseases. 
3. Omics strategies and single molecule approaches 
The major differences between omics strategies and single molecule approaches lies in 
throughput (hundreds of thousands versus one or a few), but also in experimental design. 
Classic single molecule bio medical research is based on hypothesis testing, building new 
experiments based on prior observations and theory, such that classic scientific research 
tends towards a reductionist approach in understanding disease and disease processes, 
owing to the limitations of most technologies and the complex nature of pathological 
systems. After a first omics hypothesis generating approach, classic single molecule 
experiments should ensue, in order to delve further into the mechanisms of the newly 
generated hypotheses. (Naesens and Sarwal, 2010) 
The development of genomics and transcriptomics notwithstanding, gene polymorphisms 
and transcript levels correlate incompletely with the expression level of the functionally 
active proteins, which more accurately reflect actual cellular events. This poor correlation 
between genotype, gene expression and the localization or activity of the proteins is caused 
by the complex regulation of the transcription and the post translational modifications that 
change the properties of proteins. Proteins therefore provide a better picture of events that 
occur inside an organism and provide ideal biomarkers for disease conditions. (Abbott 1999, 
Quintana et al 2010 and Righetti and Boschetti 2007) 
4. Proteomics technology  
Proteomics methods are also increasingly being used in the field of organ transplantation. 
Because urine is the ideal non invasive specimen for renal diseases, the number of proteomic 
studies of urine has surged, and urine proteomics are a promising tool for the non invasive 
diagnosis of acute rejection and chronic allograft histological damage. 
New tools and new applications of chemical technologies have revolutionized proteomics 
and peptidomics last years. Proteomics tools include gel electrophoresis (like one 
dimensional gel electrophoresis (1D); two dimensional gel electrophoresis (2D)) and gel 
free methods using mass spectrometry (like matrix-assisted laser ionization (MALDI); 
liquid chromatography mass spectrometry (LC-MS); surface-enhanced laser 
ionizationwith time of flight mass spectrometry (SELDI-TOF-MS)) (Naesens and Sarwal, 
2010). 
Proteome analysis of urine requires fractionation to reduce complexity of the sample. 
Fractionation can be obtained by different techniques. These fractions are subsequently 
analyzed by a mass spectrometer (MS) where the relative abundance of the different 
proteins and peptides is determined. Bioinformatics treatment of the protein data in 
combination with the fractionation parameters yields protein profiles representing the 
partial protein content of samples (Fig. 2) 
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Fig. 2. Proteome analysis of urine requires fractionation to reduce complexity of the sample. 
Fractionation can be obtained by different chromatographic techniques or 2DE-PAGE. 2 
These fractions are subsequently analyzed by a mass spectrometer (MS) 3 Bioinformatics 
treatment of the obtained data give us the sample proteome. 
4.1 Urine sample: Collection, storage and preparation 
Sample collection, storage and preparation it is a crucial issue, and many of the techniques 
described later requires different preparation methods. (Lee et al 2008) 
Collection 
The volume, protein concentration and composition of urine show considerable variation 
among the day. There is no ideal time of day to collect urine specimens for proteomics, but it 
is preferable to obtain samples at the same time of the day to minimize variations. The first 
morning void could be contaminated by cells from the lower urinary tract and bacteria 
harbored in the urinary tract. 24 hour samples have the problem of protein degradation. The 
second void of the morning could be one of the best samples that could be used, because it is 
easy to obtain when patients come to hospital and could be quickly processed.  (O'Riordan 
et al 2006) 
Some intra-patient variability in the urine proteome has been previously observed, but other 
investigations have identified only minor variations in samples collected for up to a year. 
Individual fluctuations seem to be minimally affected by diet and exercise. The relative 
influence of exogenous and endogenous factors needs further exploration, but should be 
considered when planning protocols and in interpretation of data (Akkina et al 2009).  
Storage 
The addition of protease inhibitors, filtration, centrifugation before and after freezing to 
reduce contamination by proteins leaking cellular debris and bacteria it is necessary. It is 
necessary to do some test to confirm the absence of red blood cells and leukocytes to avoid 
possible contamination of the samples. 
Repeated freezing and thawing is known to fragment certain proteins, such as IgG and ┙-1-
antitrypsin, and should be avoided. Urine stored at 37 °C can exhibit specific protease 
activity. An advantage of urinary proteomics is that the analytical reproducibility of the 
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urine proteomic profile is unaffected by long term freezing, remaining stable for several 
years, even when stored at -20ºC (O'Riordan et al 2006).  
Preparation 
The presence of several excessively abundant urinary proteins, among them albumin and 
uromodulin (uromodulin is most abundant in normal urine, whereas albumin predominates 
in urine from diseased kidneys), can interfere with analyses. Depletion of these abundant 
proteins can increase the relative concentration and odds of detecting lower abundance 
proteins, but with the depletion we can lose some not abundant proteins (Hewitt et al 2004). 
Isolating or concentrating urinary proteins may be essential in low concentration specimens, 
particularly for gel-based studies. Numerous methods have been compared including 
precipitation with organic solvents, centrifugal filtration, lyophilization and ultrafiltration 
but with varying results. Precipitation with Trichloroacetic Acid gave good qualitative yield.  
Reverse phase extraction has also been shown to be effective in specimen concentration as 
well as for desalting urinary peptides and segregating lower-molecular weight proteins 
(Bañón-Maneus et al 2007 and 2011).  
4.2 Separation of proteins 
Mono-and two-dimensional electrophoresis (2D-PAGE) 
Two-dimensional electrophoresis was first described by O’Farrell over 30 years ago. The 
technology used for separation of proteins is polyacrylamide gel electrophoresis. For many 
proteomic applications, electrophoresis in one dimension is the method of choice. The 
proteins are separated according to their mass and how the proteins are solubilized in 
sodium dodecyl sulfate (SDS) there are generally no problems of solubilization. It is a 
simple, reproducible and allows the separation of proteins of 10-300 kDa. The 2D-PAGE 
two-dimensional electrophoresis allows separate thousands of proteins in a single 
experiment, and is currently the most efficient method for separating very complex protein 
mixtures. It is based on a separation of proteins according to the isoelectric point, followed 
by separation of proteins according to their molecular mass (Fig. 3). The first dimension 
separation is performed by isoelectric focusing, during which proteins are separated in a pH 
gradient until reaching a position where its net charge is zero, its isoelectric point (Fig. 4A). 
In a second dimension, proteins are separated by molecular weight in polyacrylamide gels 
(Fig. 4B). The high resolution of the technique is that the two separations are based on 
independent parameters. The key innovation for the 2D-PAGE was the development of gels 
with immobilized pH gradient (IPG). For detection of proteins has traditionally been using 
the radioactive labeling or staining with Coomassie blue or silver, for greater sensitivity. It 
also has developed a silver staining method compatible with surface protein digestion and 
mass spectrometry (Fig. 3) (Bañon-Maneus et al 2010, Oh et al 2004 and Thongboonkerd 
2002). A recent development of 2D-PAGE technology is DIGE (Difference in Gel 
Electrophoresis), explained later. 
The 2D-PAGE also has limitations: It is a very demanding technique, is time consuming, and 
difficult to automate, is limited by the number and type of proteins to solve; the very large 
or hydrophobic proteins do not enter the gel during the first dimension while proteins very 
acidic or very basic not well resolved, and in the presence of abundant proteins are difficult 
to detect low abundance proteins. Some of these problems can be resolved by fractionation,  
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Fig. 3. 2D-PAGE workflow. After the protein extraction of the samples proteins were firs 
separated by the isoelectric point and after that by molecular weight. After the 2DE-PAGE 
staining the images were analyzed by finding of differential spots, that after the scission 
were identified by distinct Mass spectrometry approaches.  
the use of certain solubilization conditions and the use of IPGs with different pH ranges. 
(Table 2) (Yoshida et al 2005) 
Liquid chromatography 
LC is a physical method of separation based on the distribution of the various components 
of a mixture into two immiscible phases one stationary and the other mobile. The mobile 
phase involves a liquid that flows through a column containing the steady phase. Classic LC 
is carried out in a column which is generally made of glass and filled with the steady phase. 
The steady phase may be a solid with different chemical properties which give rise to 
different types of chromatography – ion exchange chromatography, reverse-phase 
chromatography, and others. The mobile phase may be a pure solvent or mixture of 
solvents. After placing the sample on the upper part, the mobile phase flows through the 
column as a result of gravity. To improve the efficiency of separations, the size of steady 
phase particles was gradually diminished down to microns, and this called for high 
pressures to ensure mobile phase flow. (Table 2) (Cutillas et al 2003 and Mann et al 2002) 
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Fig. 4. A) IEF Samples were loaded into a dry polyacrylamide gel strips with an 
immobilized pH gradient for the separation by isoelectric point B) Second dimension, strips 
were loaded on the top of polyacrylamide gel and proteins were separated by molecular 
weight 
 
Technology ADVANTAGES DISADVANTAGES 
2DE-MS For large molecules, sequencing of 
biomarkers easy to perform from spots 
Restricted to selected IP, difficult to 
automate, time consuming, small 
molecules not detected (<10 kDa) 
SELDI-TOF High throughput, easy-to-use, 
automation, low sample volume 
Restricted to selected proteins, low 
resolution MS, lack of comparability. 
LC-MS Automation, multidimensional, high 
sensitivity, used for detection of large 
molecules (>20 kDa) after tryptic 
digest, sequence determination of 
biomarkers provided by MS/MS 
Reassembly of tryptic peptides into their 
precursor molecule can be problematic, 
time consuming, relatively sensitive 
toward interfering compounds, medium 
throughput 
CE-MS Automation, high sensitivity, fast, low 
sample volume, multidimensional 
Generally not suited for larger 
molecules (>20 kDa) 
2DE–MS, Two-dimensional gel-electrophoresis followed by mass spectrometry; LC–MS, liquid 
chromatography coupled to mass spectrometry, SELDI–TOF, surface-enhanced laser 
desorption/ionization coupled to mass spectrometry; CE–MS, capillary electrophoresis coupled to 
mass spectrometry 
 
Table 2. Advantages and disadvantages of proteomic techniques for use in urinary 
biomarker discovery 
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High Performance Liquid Chromatography 
High-performance liquid chromatography (HPLC) involves dissolving the protein mixture 
in buffer and pumping it through a series of columns. The columns are composed of 
materials with various physical, chemical and immunological properties, which bind 
different proteins with varying degrees of affinity depending on the complementary protein 
properties. The proteins can then be eluted from the columns. The properties on which 
separation can be based are numerous; the elements most frequently applied to urine are 
size exclusion (based on size), reverse phase (based on hydrophobicity), strong and weak 
cation binding, and affinity binding (i.e. an immunoglobulin adsorbing to protein of 
interest). (Bañón-Maneus et al 2007) 
Capillary electrophoresis 
In a silica capillary, proteins or peptides are separated as a function of charge at a desired 
pH by an electric field in which the capillary is housed. Like HPLC, this method can be 
applied to intact proteins, as well as digests. Although a powerful separation technique, 
capillary electrophoresis (CE) does not yield reliable quantitative information. (Table 2) 
(Schiffer et al 2006)  
Mass spectrometry (MS): Identification and characterization of proteins  
Proteins can be identified by various means, among which include the sequencing of the N-
terminal specific antibody detection, amino acid composition, co-migration with known 
proteins and over-expression and depletion of genes. All these methods are generally slow, 
laborious or expensive and therefore not suitable for use as large-scale strategies. However, 
the MS, because of its rapidity and high sensitivity, has become the preferred method for 
identifying large-scale protein and the first step to study the proteome of different 
organisms. It also allows the characterization of post-translational modifications that have 
physiological relevance, such as glycosylation and phosphorylation. To analyze proteins by 
mass spectrometry these must be converted into peptides through proteolysis, usually with 
trypsin (Mauri et al 2009). This so robust technique involves (Fig. 5):  
 Conversion of peptides into gas phase ions using soft ionization techniques such as 
ionization-assisted laser desorption matrix (MALDI) from a sample in solid form, or by 
electrospray ionization (ESI) of a sample solution.  
 Separation of ions according to m/z (mass / charge) in a mass analyzer (e.g. type 
analyzer TOF (Time Of Flight), quadrupole, ion trap, etc.). Optional Fragmentation of 
selected peptide ions through goal decomposition stable (or PSD technique: post source 
decay) or by collision-induced dissociation (CID) conducted in a tandem mass 
spectrometer combining two different analyzers.  
 Measurement of the masses in a detector obtaining a mass spectrum that reflects the 
abundance of ions versus their value m / z  
For protein identification it has been developed two strategies:  
- Identification by peptide fingerprint (PMF: peptide mass fingerprinting) or peptide 
mapping using MALDI-TOF spectrometer type.  
- Identification of peptides obtained by fragmentation of whole or partial sequence of 
amino acids (sequence tag) using a tandem mass spectrometer. 
Peptide mass fingerprinting  
Peptide mapping is a technique used routinely to identify proteins quickly, usually from 
SDS-PAGE gels or 2D-PAGE and that is normally performed in a mass spectrometer type 
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MALDITOF. In this approach the protein is digested with an enzyme, usually trypsin. The 
sample is incorporated into a metal plate with a matrix and crystals formed upon 
evaporation. Subsequently, the sample is irradiated with laser to ionize the molecules. The 
ions are accelerated by an electric field towards a detector, the value m / z of each ion is 
determined by the flight time from the source reaching the detector. 
 
 
 
Fig 6. Urine samples were concentrated and separated from organic salts by solid phase.  
Each sample was applied and dried on an uncoated MALDI target plate using the sandwich 
technique.  
The peptide fingerprint (PMF) of a particular protein is a set of peptides generated by 
digestion of a specific protease. These experimental peptide masses are compared with 
theoretical peptide masses of proteins present in databases by developing various 
algorithms available on the network. For the correct identification of the protein mass 
requires a large number of peptides matching the theoretical masses of peptides, covering 
part of the protein sequence database. The limitations of mass spectrometry are that the 
ionization of peptides is selective and not quantitative. In an equimolar set of peptides 
derived from digestion of a protein, some peptides may not be detected and the rest of them 
can be a large variation in signal intensity. If the amount of protein in the gel is small, the 
number of peptides observed can be small and therefore the protein can not be identified 
with certainty. The MALDI-TOF MS is of little use to analyze protein mixtures. Very clear 
protein spots from 2D gels can contain several proteins (Bañón-Maneus et al 2007 and 
Gazzana  and Borlak  2007) 
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Peptide sequence  
It is a strategy to identify proteins not annotated in databases or for the ambiguous 
identification by MALDI-TOF. The tandem mass spectrometer MS / MS can also determine 
the amino acid sequence. Ion is selected by a mass spectrometer and fragmented first 
collision with a gas and the fragments are analyzed in a second spectrometer. Peptide 
sequence can be done with MALDI ionization source type or ESI. (Gazzana and Borlak  
2007) 
Surface-enhanced laser desorption/ionization (SELDI) 
SELDI–MS incorporates chromatographic and MS principles in a single platform. An 
activated surface on a ‘chip’ binds proteins on the basis of their chemical and physical 
properties; unbound proteins are washed off. A subset of the proteome is thus selected and 
the chip plugs directly into the mass spectrometer for analysis. This is a high-throughput 
screening technique that facilitates relative abundance profiling of individual proteins from 
different samples. Although the approach can be extremely useful for screening 
peptide/protein samples for recognition of biomarker ions, it does not enable the protein 
origin of these ions to be reliably discerned. Other disadvantages are  use of relatively low-
resolution MS, the fact that only a subset of the proteome can be studied on any particular 
surface, and that the performance varies between different machines (as does performance 
of a single machine over time). (O´Riordan et al 2006) 
4.3 Expression level quantitative techniques  
The main application of proteomics is the study of protein expression profile. There are two 
strategies that enhance the study of differential protein expression between different 
samples, the gel based and the free gel technologies. 
Gel based quantitative proteomics: DIGE 
Also recently described an approach based on the labeling of proteins with different 
fluorophores and the separation of samples by 2D-PAGE in the same gel. This methodology, 
called DIGE (Differential Gel Electrophoresis), minimizes the variability of the gels 
decreased analysis time and allows quantification of very specific expression profile. Briefly, 
two samples are differentially labeled with two different fluorescence CyDyes (p.e, Cy3 and 
Cy5), mixed, and then resolved simultaneously within the same 2DE gel. The introduction 
of a pooled internal standard labeled with a third dye (p.e. Cy2) improves the accuracy of 
protein quantification between samples from different gels allowing detection of small 
changes in protein levels. Differentially expressed proteins could be identified using protein 
fingerprinting MS methods as modern matrix-assisted laser desorption/ionization-time of-
flight MS (MALDI-TOF-MS) instrumentation. (Alban et al 2003, Shaw et al 2003, Unlu et al 
1997 and Wu 2006)  
Gel Free quantitative proteomics: ICAT, iTRAQ, SILAC 
The ICAT (isotope-coded affinity tags), which can determine the relative amount of 
protein between two samples. The two protein samples are labeled with the ICAT reagent 
light or heavy (as hydrogen or deuterium leads). This reagent binds to cystein and 
contains biotin to facilitate purification. Subsequently, the two samples are mixed and 
digested with trypsin. The peptides marked with ICAT reagent are separated in an 
affinity column and analyzed by MS. The relative intensity of the peptides identical in 
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each sample (differ in a mass of 8 Da) are abundant protein from which they came. The 
fragmentation of the peptide by MS / MS led to the identification of the protein (Sobhani 
2010). 
An improved approach analogous to ICAT has been developed called iTRAQ (Applied 
Biosystems). The technique is based upon chemically tagging the N-terminus of peptides 
generated from protein digests that have been isolated from cells, tissues, biological fluids in 
two different states (Chen et al 2010). The two labeled samples are then combined, 
fractionated by nanoLC and analyzed by tandem mass spectrometry. Database searching of 
peptides data fragmentation provides the identification of the labeled peptides and hence 
the corresponding proteins. Fragmentation of the tag attached to the peptides generates a 
low molecular mass reporter ion that is unique to the tag used to label each of the digests. 
Measurement of the intensity of these reporter ions, enables relative quantification of the 
peptides in each digest and hence the proteins from where they originate. There are four 
tags available enabling four different conditions to be multiplexed together in one 
experiment. (Gigy et al 1999)  
Stable isotope labeling with amino acids in cell culture (SILAC) is a simple and 
straightforward approach for in vivo incorporation of a label into proteins for mass 
spectrometry (MS)-based quantitative proteomics. SILAC relies on metabolic incorporation 
of a given 'light' or 'heavy' form of the amino acid into the proteins. The method relies on the 
incorporation of amino acids with substituted stable isotopic nuclei (e.g. deuterium, 13C, 
15N). Thus in an experiment, two cell populations are grown in culture media that are 
identical except that one of them contains a 'light' and the other a 'heavy' form of a particular 
amino acid (e.g. 12C and 13C labeled L-lysine, respectively). When the labeled analog of an 
amino acid is supplied to cells in culture instead of the natural amino acid, it is incorporated 
into all newly synthesized proteins. After a number of cell divisions, each instance of this 
particular amino acid will be replaced by its isotope labeled analog. Since there is hardly any 
chemical difference between the labeled amino acid and the natural amino acid isotopes, the 
cells behave exactly like the control cell population grown in the presence of normal amino 
acid. It is efficient and reproducible as the incorporation of the isotope label is 100%. This 
technology it is not yet available for human urine proteomics but it could be used in 
experimental models by the administration of pellet food with the isotope enhanced. (Quan 
et al 2011)  
Protein Arrays  
Protein arrays are rapidly being developed for the characterization of activities and for 
detecting protein-protein interactions on a large scale. Like DNA arrays, protein arrays will 
be essential for basic research and more applied research to drug discovery and 
development of diagnostic methods. In a pioneering work done by the group of Snyder, we 
developed a chip with 6,000 yeast proteins to identify new proteins that interact with 
calmodulin or phospholipids. The proteins were obtained by cloning the corresponding 
ORFs and each protein was expressed fused to GST (glutathione S-transferase) and a 
histidine tag. This important work showed that it is possible to prepare microarrays with 
thousands of proteins and used to study interactions. However, although significant 
progress has been made for the preparation of the arrays, we still need to face several 
technological challenges to allow allowing the use of this tool to many researchers. (Zhu et 
al, 2000) 
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5. Protein biomarkers for kidney transplantation 
Currently follow up of renal transplant recipients is done by the physicians checking  serum 
creatinine and glomerular filtration rate (GFR), but neither is particularly sensitive or 
specific and may not reflect early alterations (Paul 2009 and Nankivell 2003). At present, 
biopsy allograft is regarded as the gold standard for the diagnosis of kidney diseases 
allowing its early detection; however, this is a costly procedure that is associated with 
clinical complications (Beckingham et al 1994). 
5.1 Acute renal allograft rejection 
One of the major problems in renal transplantation is acute renal allograft rejection. Acute 
rejection is one of the key factors that determine long term graft function and survival in 
renal transplant patients. This fatal complication is inevitable if the diagnosis is delayed.  
Mainly for groups reported urinary proteomic approach for acute rejection. Interestingly, 
each group found a different pattern of protein biomarkers that were associated with 
allograft rejection. These differences are not surprising, as each study had differences in 
disease definition, sample collection and handling, protocol for protein and data analysis. 
(Rush and Nickerson 2011)  
Clarke et al reported the comparison between 17 urines from rejecting patients to urines 
from 15 stable (not biopsied) controls. Proteomic analysis of the urine was done using 
SELDI15 and ProteinChip Arrays with immobilized metal affinity (IMAC-3) and 
hydrophobic (H4) surface. The best candidate biomarkers were four proteins of molecular 
around 7 kd and one of 13.4 kd. A separate analysis using the CART algorithm in the 
Ciphergen Biomarker Pattern Software using two different proteins of 3.4 kd and 10 kd, 
respectively, correctly classified 91% of the 34 urine specimens in the training set, producing 
a sensitivity of 83% and a specificity of 100%. (Clarke et al 2003) 
O’Riordan et al reported on the urine proteome in 23 renal transplant patients with biopsy-
proven acute rejection, 22 recipients with stable graft function (characterized by serum 
creatinine) and 20 healthy volunteers (27). The urine was preadsorbed on four different chip 
surfaces, and was analyzed by SELDI-TOF. Protein masses that were useful in the 
construction of the classification algorithms were of approximately 2.0, 2.8, 4.8, 5.8 7.0, 19.0 
and 25.6 kd. Patients that had experienced acute rejection could be distinguished from stable 
patients with a sensitivity of 90.5% to 91.3% and a specificity of 77.2% to 83.3%, depending 
on the classifier used. (O’Riordan et al 2004) 
The main drawback with this two studies is that control samples (stable renal transplant 
recipients) where characterized by a serum creatinine and no biopsies were done at the time 
of urine collection. 
Wittke et al reported the analysis done by CE-MS from 19 patients with subclinical or 
clinical rejection, 10 patients with urinary tract infection but without rejection, and 29 
patients without acute rejection or urinary tract infection (28). These patients were from a 
centre that performs protocol biopsies, and the urine samples were obtained at the time of 
protocol biopsy. An additional cohort of 66 healthy controls was studied. The authors were 
able to discriminate the rejecting patients from those without rejection in 16 of 19 patients 
using combinations of 16 polypeptides. (Wittke et al 2005) 
Finally, Schaub et al sought to determine whether such candidate proteins can be detected 
in urine using mass spectrometry. Four patient groups were defined on the basis of allograft 
function, clinical course, and biopsy result. Four groups where analyzed: acute clinical 
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rejection, stable transplant, acute tubular necrosis, and recurrent (or de novo) 
glomerulopathy. Urines were collected the day of the allograft biopsy. As a normal control 
group, urines from healthy individuals were analyzed, as well as 5 urines from non-
transplanted patients with lower urinary tract infection. Three prominent peak clusters were 
found in 94% of the patients with acute rejection episodes, but only in 18% of patients 
without clinical and histologic evidence for rejection and in any of normal controls. In 
addition, the presence or absence of these peak clusters correlated with the clinicopathologic 
course in most patients. Acute tubular necrosis, glomerulopathies, lower urinary tract 
infection, and cytomegalovirus viremia were not confounding variables. (Schaub et al 2004)  
In conclusion, proteomic technology together with stringent definition of patient groups can 
detect urine proteins associated with acute renal allograft rejection. Identification of these 
proteins may prove useful as non-invasive diagnostic markers for rejection and the 
development of novel therapeutic agents. 
5.2 BKV renal allograft nephropathy 
BKV renal allograft nephropathy (BKVAN have an important role in development of renal 
allograft dysfunction (Fishman 2002). About 6-10% of these patients develop BKVAN, and 
the reported graft loss rate in this group has been as high as 50% (6,7). BKVAN can resemble 
acute allograft rejection (AR) and differentiation between them can be challenging both at 
histological and molecular levels (Fishman 2002). The discrimination is important because 
the treatment is diametrically opposite for the two conditions. In general, 
immunosuppression needs to be reduced in patients with BKVAN, whereas it is increased 
in AR. Currently, these two clinical conditions cannot be differentiated in a reliable way on 
the basis of clinical and laboratory findings and a definitive diagnosis of BKVAN requires 
allograft biopsy. Even the histological differentiation of BKVAN from AR can be difficult 
unless viral inclusions are seen on allograft biopsy (Fishman 2002). 
Jahnukainen et al used Surface-enhanced laser desorption/ionization (SELDI) time of flight 
mass spectrometry to compare the urinary of patients with BKVAN, AR and stable graft 
function. They were able to detect several peaks that were differentially expressed in the 
BKVAN group compared with both the AR and stable function groups. Peaks that 
corresponded to m/z values of 5.872, 11.311, 11.929, 12.727, and 13.349 kD were significantly 
higher in patients with BKVAN. As Mannon et al showed significant similarity of 
transcriptional expression of molecules associated with inflammation and fibrosis between 
BKVAN and AR (Mannon et al 2005). This probably is due to the similarity of the 
inflammatory response and leakage of inflammation related small molecular weight proteins 
into urine in both conditions. The limitations of this study are that all of their analyses were 
based on a limited sample size, and their results on the sensitivity and the specificity of the 
various algorithms should be interpreted with caution. A true assessment of sensitivity and 
specificity of the SELDI technique and the various models tested in this report cannot be 
determined until an independent validation set that is derived from another set of patients is 
assessed. Proteomic marker(s) profiles, together with plasma and urine BKV PCR and clinical 
information, may help in making differentiation of BKVAN from AR in a non-invasive 
manner. Histological verification of BKVAN probably will continue to be required for the 
foreseeable future, but it is likely that proteomic biomarkers could be used in deciding when a 
biopsy is necessary. Further studies on a larger number of patients are needed to validate these 
findings and to detect the identity of the significantly different peaks to develop robust, non-
invasive methods for BKVAN diagnostics. (Fishman 2002). 
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5.3 Chronic allograft rejection 
The survival half-life for kidneys from deceased donors is approximately 11 yr, and the 
pathogenesis of chronic allograft rejection (CAD) is multifactorial (Mauiyyedi et al, 2001). 
Analyses of graft histology reflected in the revised Banff criteria indicate CAD can be 
subcategorized, in part, on the basis of evidence of local inflammation and the presence or 
absence of interstitial fibrosis and tubular atrophy (IF/TA) (Solez et al, 2008). Although 
specific inciting factors are difficult to define in each situation, distinct histopathologic 
entities often correlate with likely causes. For example, calcineurin inhibitor toxicity 
frequently manifests as IF/TA without inflammation; ongoing cellular alloimmunity 
presents histologically with tubulitis with or without IF/TA; C4d staining suggests 
transplant glomerulopathy with or without IF/TA; and detectable, donor-specific serum 
antibodies underlie antibody-mediated allograft injury (Solez et al, 2008). 
Because only a subset of patients develop CAD and at present physicians do not have the 
ability to reverse chronic fibrotic kidney damage, it is essential that the transplant 
community develop reliable and noninvasive approaches to predict which patients are most 
likely to develop graft failure so that appropriate interventions can be instituted before graft 
failure becomes clinically apparent (Mauiyyedi et al, 2001). 
Urine proteomic profiling of CAD has been investigated in a few studies to date. Using 
SELDI as screening methodology and liquid chromatography coupled to mass spectrometry 
(LCMS) to obtain protein ID information, O’Riordan et al studied the urinary proteome of 75 
renal transplant recipients and 20 healthy volunteers. Patients could be classified into 
subgroups with normal histology and Banff CAN grades 2-3 with 86% sensitivity and 92% 
specificity. Several urinary proteins associated with advanced CAN were identified 
including a1-microglobulin, b2-microglobulin, prealbumin, and endorepellin, the 
antiangiogenic C-terminal fragment of perlecan. Increased urinary endorepellin was 
confirmed by ELISA and increased tissue expression of the endorepellin/perlecan ratio by 
immunofluoresence analysis of renal biopsies (O’Riordan 2008). 
Our group is also investigating the utility of proteomic analysis of urinary samples as a non-
invasive method to detect and evaluate CAD. We did the two main proteomic approaches, 
gel based and gel free approach. Proteomics based on two-dimensional electrophoresis (2-
DE) has been optimized with the development of Difference Gel Electrophoresis (DIGE). A 
proteome map of stable renal patients as a reference protein database, to validate the utility 
of 2D-DIGE technology in finding new candidates as CAD urinary biomarkers were 
established. Morning spot urine of kidney transplant patients with a biopsy two years after 
transplantation with CI/CT score 0-I-II/III (n=8/group) was collected. 2D silver stained and 
mass spectrometry (MS) analyses were used to establish the proteome map and 2D-DIGE 
and MS were used to identify proteins exhibiting differential abundance. In this work not 
only the urinary proteome of renal stable patients was established but we were able to 
identify 11 proteins with elevated levels on advanced CAD: ┚-2 microglobulin, MASP-2, ┙-
1-┚-glycoprotein, leucine-rich ┙-2-glycoprotein 1, ┙-1-antitrypsin, Gelsolin precursor, AIF-
like mitchondrion-associated inducer of death, heparan sulfate proteoglycan, anti-TNF-┙ 
antibody light-chain, immunoglobulin lambda light chain and dimethylarginine- 
dimethylaminohydrolase 2 and wnt-1. Eight of these proteins, ┙-1-antitrypsin, 
angiotensinogen, ┚-2-microglobulin, dimethyl-arginine dimethylaminohydrolase-2, 
immunoglobulin lambda light chain, transferrin, trypsin precursor, and Zn-┚-2-
glycoprotein, have been described in other renal injuries thus reducing their validity as 
biomarkers of, but we identified wnt-1, a protein from wnt/┚-catenin pathway that has been 
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described as a pathway really involved in fibrosis in other organs such as lung (Bañón-
Maneus et al 2010).  
Proteomic analysis using solid phase extraction as protein purification method and Protein 
profiling by MALDI-TOF was also performed. This is a relatively simple proteomic 
approach that allows rapid differential diagnosis of patients and information transfer 
between the laboratory and the clinical context. Fifty individuals: 32 patients with chronic 
allograft dysfunction (14 with pure interstitial fibrosis and tubular atrophy, and 18 with 
chronic active antibody-mediated rejection) and 18 controls (8 stable recipients and 10 
healthy controls) were studied. Unsupervised hierarchical clustering showed good 
segregation of samples in groups corresponding mainly to the four biomedical conditions. 
Moreover, the composition of the proteome of the pure interstitial fibrosis and tubular 
atrophy group differed from that of the chronic active antibody-mediated rejection group, 
and an independent validation set confirmed the results from the training set (Quintana et al 
2009). With the gel free approach we detected (by LC-M/MS) and quantified (by LCMS) 
6000 polypeptide ions in undigested urine specimens across 39 CAD patients and 32 control 
individuals. Although unsupervised hierarchical clustering differentiated between the 
groups when including all the identified peptides, specific peptides derived from 
uromodulin and kininogen were found to be significantly more abundant in control than in 
CAD patients and correctly identified the two groups. These peptides are therefore potential 
biomarkers that might be used for the diagnosis of CAD. In addition, ions at m/z 645.59 and 
m/z 642.61 were able to differentiate between patients with different forms of CAD with 
specificities and sensitivities of 90% in a training set and, significantly, of 70% in an 
independent validation set of samples. Interestingly low expression of uromodulin at m/z 
638.03 coupled with high expression of m/z 642.61 diagnosed CAD in virtually all cases 
(Quintana et al 2009). 
This suggests that urinary proteome analysis can be used for the non-invasive monitoring of 
renal transplant patients, although it awaits validation in larger cohorts. 
6. Conclusion 
In summary, the application of proteomics in the field of renal and organ transplantation 
opens important options diagnostic and prognostic purposes. At present, urinary 
proteomics allows us a more early and accurate diagnosis of acute rejection by the 
experimental determination of peptides in the urine. The differential detection of peptides at 
diverse stages of the NCT in acute rejection allows us a better way to understand rejection 
and tolerance. The combined information derived from genomics and proteomics will lead 
us to consistently reduce the risk factors for graft failure (acute rejection, ischemia-
reperfusion, immunosuppression, NCT), with increased life of the organs and improved 
patient’s quality of life, because proteomics is one of the fields that can help to establish a 
connection between genomic sequences and biological behavior, constituting an important 
tool in functional analysis of genes of unknown function. The main advantage of a urine 
proteomic study as a source of markers for the detection of renal disease in the transplant is 
that urine is a fluid readily available and non-invasive. There are multiple proteomic 
techniques although it is noteworthy that, even though the results that each technique offers 
are very consistent, none is sufficient by itself to obtain and complete proteome and is 
advisable to combine several of the techniques described. Therefore, the primary application 
of proteomics is the search for markers that could be the basis for the realization of a 
microarray of proteins with diagnostic potential. 
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